Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 1999

View Archived Issues

Significant events at VaxGen in third quarter

OHSU study will evaluate vitamin D in patients with recurring prostate cancer

Pharming completes first phase II trial in infants with Pompe's disease, reports R&D progress

Nine-month highlights at Novo Nordisk

FDA authorizes OrthoLogic to proceed with Chrysalin trials in fracture healing

FluMist BLA filing delayed; 2001-2002 flu season targeted for launch

Chronic oral treatment with SR-121463 improves water retention in cirrhotic rats

Cardioprotective ginkgolides under study at CNRS

Chromanone derivatives for androgen-dependent and other disorders disclosed by Novartis

COX-2 inhibitor MK-663 provides significant pain relief in osteoarthritic patients

Isis presents findings for antisense treatment of RA at ACR

Cardiovascular and renal agents from SB act as endothelin antagonists

Schering-Plough presents dual NK1/NK2 antagonists and their use in asthma, allergies, etc.

Fournier's new bradykinin antagonists particularly useful for asthma, rhinitis

Hydroxamate-based metalloproteinase inhibitors in the P&G pipeline

Centaur presents new antiarthritic drug candidate, the free radical spin trap NRT-115

Beta-L-FD4C compared to lamivudine in woodchuck model of chronic HBV infection

News from ACR/ARHP: Amgen's TNF-targeting therapy is effective in RA

Safety and preliminary efficacy of HBV/MF59 vaccine: data presented at AASLD

DAPD and L-FMAU compared for in vitro anti-HBV activity using wild-type and resistant strains

Anakinra plus methotrexate effective, safe in patients not responding to MTX alone

Beneficial preventive and therapeutic effects of halofuginone in liver cirrhosis

Vitamin D3 analogues may allow use of minimum doses of ciclosporin in ulcerative colitis

OSI and Sankyo renew influenza collaborative agreement

Two Amgen antiarthritics are better than one: synergistic effects of cytokine inhibitors

FDA accepts NDA for tacrolimus ointment

7th UEGW: anti-IL-6R MAb evaluated as Crohn's disease Rx

Cel-Sci, Johns Hopkins collaboration centers on novel strategy for treating autoimmune disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.